Irinotecan Pharmagen (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside tumor cells to SN‑38, an active metabolite that inhibits the enzyme topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents DNA re‑ligation during replication, leading to DNA strand breaks and ultimately causing cancer cell death.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as cancer type, treatment protocol, patient weight, organ function and prior therapy. Typical regimens involve an intravenous infusion given every two to three weeks, but the exact amount and schedule are determined by the treating physician.

Safety data for Irinotecan during pregnancy and lactation are limited, and the drug is classified as contraindicated in these situations. It is recommended that women of childbearing potential use effective contraception and avoid breastfeeding while receiving Irinotecan therapy.

To place an order, submit an enquiry on the Irinotecan Pharmagen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Irinotecan and topotecan are the two main topoisomerase I inhibitors used in oncology. Irinotecan is generally preferred for colorectal, lung and gastric cancers, while topotecan is more commonly used in ovarian and small‑cell lung cancers. Differences include dosing schedules, metabolic pathways (Irinotecan relies on UGT1A1 conversion) and side‑effect profiles, such as a higher incidence of severe diarrhea with Irinotecan.

Irinotecan Pharmagen must be stored refrigerated at 2‑8 °C. The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before administration, the product is reconstituted with the appropriate diluent under aseptic conditions and used within the time frame specified in the product label.

Irinotecan is given as an intravenous infusion. After reconstitution, the solution is diluted in a compatible IV fluid and infused over 30 to 90 minutes, depending on the prescribed regimen. Administration is performed by qualified healthcare professionals in a clinical setting, with monitoring for infusion‑related reactions and immediate management of any adverse events.

The most serious risks include severe neutropenia leading to infection, febrile neutropenia, life‑threatening diarrhea or colitis, and hepatic toxicity manifested by marked elevations in liver enzymes or bilirubin. Patients should be educated to report fever, persistent diarrhea, jaundice or any signs of infection promptly for early intervention.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its components, those with severe bone‑marrow suppression (e.g., absolute neutrophil count <1,500 µL), uncontrolled infections, or significant hepatic impairment. Caution is also advised for individuals with UGT1A1 polymorphisms that predispose them to increased toxicity.